AI Tokens
Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Analysis of Short-term (Operating) Activity Ratios

Microsoft Excel

Short-term Activity Ratios (Summary)

Turnover Ratios

Average No. Days

Cytokinetics Inc., short-term (operating) activity ratios

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Turnover Ratios
Receivables turnover 643.46 1.36 12.63 5.20 14.12
Payables turnover 3.69 3.34 6.94 3.29 8.37
Working capital turnover 0.13 0.15 0.13 0.13 0.17
Average No. Days
Average receivable collection period 1 269 29 70 26
Average payables payment period 99 109 53 111 44

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The short-term operating activity ratios exhibit significant volatility and unconventional patterns, particularly regarding the management of receivables and payables. A general lack of stability in asset conversion cycles is evident over the five-year period, while working capital efficiency remains consistently low.

Receivables Management
An extreme fluctuation in the receivables turnover ratio is observed, moving from 14.12 in 2018 to a low of 1.36 in 2021, before spiking to 643.46 in 2022. This volatility is mirrored in the average receivable collection period, which surged to 269 days in 2021, indicating a severe slowdown in cash collection. However, the 2022 figure of one day suggests a nearly instantaneous conversion of receivables to cash or a fundamental change in the nature of the company's short-term assets.
Payables Management
The payables turnover ratio shows a general downward trend compared to 2018 levels, indicating a slower rotation of liabilities. Correspondingly, the average payables payment period has expanded, increasing from 44 days in 2018 to nearly 100 days by 2022. This extension in payment terms suggests a strategy of delaying outflows to preserve liquidity, with the payment cycle peaking at 111 days in 2019.
Working Capital Efficiency
Working capital turnover has remained stagnant and exceptionally low, fluctuating within a narrow range between 0.13 and 0.17. This indicates that the entity generates very little revenue relative to its invested working capital, a pattern consistent with organizations prioritizing research and development over immediate commercial scale.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Receivables Turnover

Cytokinetics Inc., receivables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Revenues 94,588 70,428 55,828 26,868 31,501
Accounts receivable 147 51,819 4,420 5,163 2,231
Short-term Activity Ratio
Receivables turnover1 643.46 1.36 12.63 5.20 14.12
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 5.16 5.63 — — —
Amgen Inc. 4.46 4.96 — — —
Bristol-Myers Squibb Co. 5.48 5.65 — — —
Danaher Corp. 6.40 6.36 — — —
Eli Lilly & Co. 4.14 4.24 — — —
Gilead Sciences Inc. 5.65 6.01 — — —
Johnson & Johnson 5.88 6.14 — — —
Merck & Co. Inc. 6.27 5.28 — — —
Pfizer Inc. 9.24 7.16 — — —
Regeneron Pharmaceuticals Inc. 2.28 2.66 — — —
Thermo Fisher Scientific Inc. 5.53 4.92 — — —
Vertex Pharmaceuticals Inc. 6.19 6.66 — — —
Receivables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 5.76 5.54 — — —
Receivables Turnover, Industry
Health Care 8.22 8.00 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Receivables turnover = Revenues ÷ Accounts receivable
= 94,588 ÷ 147 = 643.46

2 Click competitor name to see calculations.


Revenue demonstrates a consistent growth trajectory from 2019 through 2022, increasing from US$ 26.87 million to US$ 94.59 million. This expansion occurs alongside extreme volatility in accounts receivable and the corresponding turnover ratios, indicating inconsistent collection patterns over the observed five-year period.

Receivables Turnover Volatility
The turnover ratio experienced significant fluctuations between 2018 and 2020, starting at 14.12, decreasing to 5.20 in 2019, and recovering to 12.63 in 2020. This suggests alternating periods of efficiency and slowdown in the conversion of receivables into cash.
Analysis of the 2021 Efficiency Decline
A sharp contraction in the receivables turnover ratio to 1.36 is observed in 2021. This decline is directly correlated with a substantial surge in accounts receivable, which peaked at US$ 51.82 million. The data indicates a significant increase in outstanding credit or a substantial delay in payment collections during this fiscal year.
Evaluation of the 2022 Statistical Outlier
In 2022, the receivables turnover ratio reached an anomalous value of 643.46. This spike is driven by a precipitous drop in accounts receivable to US$ 147 thousand, despite revenue reaching its highest point in the period. This suggests a near-total liquidation of outstanding receivables or a fundamental shift in the company's billing and collection mechanism.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Payables Turnover

Cytokinetics Inc., payables turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Revenues 94,588 70,428 55,828 26,868 31,501
Accounts payable 25,611 21,087 8,050 8,160 3,764
Short-term Activity Ratio
Payables turnover1 3.69 3.34 6.94 3.29 8.37
Benchmarks
Payables Turnover, Competitors2
AbbVie Inc. 5.94 6.05 — — —
Amgen Inc. 4.08 4.72 — — —
Bristol-Myers Squibb Co. 3.33 3.37 — — —
Danaher Corp. 5.45 4.48 — — —
Eli Lilly & Co. 3.43 4.38 — — —
Gilead Sciences Inc. 6.25 9.36 — — —
Johnson & Johnson 2.66 2.70 — — —
Merck & Co. Inc. 4.08 2.96 — — —
Pfizer Inc. 5.04 5.53 — — —
Regeneron Pharmaceuticals Inc. 2.65 4.32 — — —
Thermo Fisher Scientific Inc. 7.67 6.83 — — —
Vertex Pharmaceuticals Inc. 3.55 4.64 — — —
Payables Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.28 4.23 — — —
Payables Turnover, Industry
Health Care 5.79 5.84 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Payables turnover = Revenues ÷ Accounts payable
= 94,588 ÷ 25,611 = 3.69

2 Click competitor name to see calculations.


An analysis of the operating activity ratios reveals a significant expansion in both revenue and accounts payable over the five-year period from 2018 to 2022. Revenues grew from 31,501 thousand US dollars in 2018 to 94,588 thousand US dollars in 2022, while accounts payable increased more aggressively, rising from 3,764 thousand US dollars to 25,611 thousand US dollars in the same timeframe.

Payables Turnover Volatility
The payables turnover ratio exhibited substantial volatility during the observed period. The ratio peaked in 2018 at 8.37, indicating a rapid settlement of obligations to suppliers. This figure dropped sharply to 3.29 in 2019, followed by a temporary recovery to 6.94 in 2020, before stabilizing at lower levels of 3.34 in 2021 and 3.69 in 2022.
Liability Management and Cash Flow Strategy
The general downward trend in the turnover ratio, relative to the 2018 baseline, suggests a shift in the company's credit management strategy. The increase in the average time taken to pay suppliers corresponds with the significant growth in total accounts payable, indicating a potential strategic effort to preserve working capital by extending payment terms.
Relationship Between Revenue Growth and Payables
While revenues increased by approximately 200% between 2018 and 2022, accounts payable increased by approximately 580%. This disproportionate growth indicates that the increase in obligations to suppliers has outpaced the growth in top-line revenue, resulting in the observed compression of the payables turnover ratio.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Working Capital Turnover

Cytokinetics Inc., working capital turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Current assets 795,186 535,672 474,221 233,752 207,674
Less: Current liabilities 84,617 71,860 31,199 26,023 22,194
Working capital 710,569 463,812 443,022 207,729 185,480
 
Revenues 94,588 70,428 55,828 26,868 31,501
Short-term Activity Ratio
Working capital turnover1 0.13 0.15 0.13 0.13 0.17
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. — — — — —
Amgen Inc. 3.82 3.37 — — —
Bristol-Myers Squibb Co. 8.30 3.95 — — —
Danaher Corp. 4.20 8.40 — — —
Eli Lilly & Co. 31.84 8.33 — — —
Gilead Sciences Inc. 8.42 8.54 — — —
Johnson & Johnson — 5.95 — — —
Merck & Co. Inc. 5.16 7.62 — — —
Pfizer Inc. 11.09 4.83 — — —
Regeneron Pharmaceuticals Inc. 0.96 1.59 — — —
Thermo Fisher Scientific Inc. 5.46 5.87 — — —
Vertex Pharmaceuticals Inc. 0.85 1.02 — — —
Working Capital Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 7.25 5.87 — — —
Working Capital Turnover, Industry
Health Care 11.30 8.57 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Working capital turnover = Revenues ÷ Working capital
= 94,588 ÷ 710,569 = 0.13

2 Click competitor name to see calculations.


Between 2018 and 2022, a substantial expansion in working capital is observed, rising from 185,480 thousand USD to 710,569 thousand USD. This growth occurred alongside a general increase in revenues, which climbed from 31,501 thousand USD in 2018 to 94,588 thousand USD by the end of 2022, despite a brief contraction observed in 2019.

Working Capital Turnover Trend
The working capital turnover ratio has remained consistently low and relatively stagnant over the five-year period. After reaching a peak of 0.17 in 2018, the ratio declined to 0.13 in 2019 and has since fluctuated minimally, ending at 0.13 in 2022.
Operational Efficiency Analysis
The persistent low value of the turnover ratio indicates that the increase in working capital has significantly outpaced the growth in revenues. The accumulation of net current assets has not resulted in a proportional increase in sales generation, suggesting a low rate of asset utilization relative to the volume of operating activity.
Comparative Growth Rates
While revenues approximately tripled between 2018 and 2022, working capital increased by nearly 3.8 times. This imbalance explains the overall downward pressure on the turnover ratio, reflecting a financial structure where liquidity growth is decoupled from immediate revenue expansion.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Receivable Collection Period

Cytokinetics Inc., average receivable collection period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data
Receivables turnover 643.46 1.36 12.63 5.20 14.12
Short-term Activity Ratio (no. days)
Average receivable collection period1 1 269 29 70 26
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 71 65 — — —
Amgen Inc. 82 74 — — —
Bristol-Myers Squibb Co. 67 65 — — —
Danaher Corp. 57 57 — — —
Eli Lilly & Co. 88 86 — — —
Gilead Sciences Inc. 65 61 — — —
Johnson & Johnson 62 59 — — —
Merck & Co. Inc. 58 69 — — —
Pfizer Inc. 40 51 — — —
Regeneron Pharmaceuticals Inc. 160 137 — — —
Thermo Fisher Scientific Inc. 66 74 — — —
Vertex Pharmaceuticals Inc. 59 55 — — —
Average Receivable Collection Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 63 66 — — —
Average Receivable Collection Period, Industry
Health Care 44 46 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 643.46 = 1

2 Click competitor name to see calculations.


The analysis of operating activity ratios reveals significant volatility in the efficiency of receivables management over the five-year period from 2018 to 2022. The metrics exhibit a non-linear trend characterized by relative stability in the early years, a severe deterioration in 2021, and an extreme statistical outlier in 2022.

Receivables Turnover
The turnover ratio fluctuated between 2018 and 2020, beginning at 14.12 and concluding that sub-period at 12.63. A sharp decline occurred in 2021, with the ratio dropping to 1.36, indicating a substantial decrease in the frequency with which receivables were converted into cash. This was followed by an unprecedented increase to 643.46 in 2022, representing a drastic shift in the relationship between net credit sales and average accounts receivable.
Average Receivable Collection Period
The collection period demonstrates a corresponding inverse relationship with turnover. After remaining relatively low in 2018 (26 days) and 2020 (29 days), the period peaked at 70 days in 2019. A critical increase was observed in 2021, where the collection period extended to 269 days, signaling a significant slowdown in payment collection. This trend reversed abruptly in 2022, with the collection period falling to 1 day, suggesting a near-instantaneous conversion of receivables or a significant accounting adjustment to the receivables balance.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Payables Payment Period

Cytokinetics Inc., average payables payment period calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data
Payables turnover 3.69 3.34 6.94 3.29 8.37
Short-term Activity Ratio (no. days)
Average payables payment period1 99 109 53 111 44
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
AbbVie Inc. 61 60 — — —
Amgen Inc. 90 77 — — —
Bristol-Myers Squibb Co. 109 108 — — —
Danaher Corp. 67 82 — — —
Eli Lilly & Co. 106 83 — — —
Gilead Sciences Inc. 58 39 — — —
Johnson & Johnson 137 135 — — —
Merck & Co. Inc. 89 123 — — —
Pfizer Inc. 72 66 — — —
Regeneron Pharmaceuticals Inc. 138 84 — — —
Thermo Fisher Scientific Inc. 48 53 — — —
Vertex Pharmaceuticals Inc. 103 79 — — —
Average Payables Payment Period, Sector
Pharmaceuticals, Biotechnology & Life Sciences 85 86 — — —
Average Payables Payment Period, Industry
Health Care 63 63 — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.69 = 99

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals significant volatility in the management of accounts payable between 2018 and 2022. The company demonstrates an inconsistent pattern in the timing of supplier payments, alternating between rapid settlement and extended credit utilization.

Payables Turnover Dynamics
A sharp contraction in payables turnover is observed from 8.37 in 2018 to 3.29 in 2019. Although a substantial recovery occurred in 2020, reaching 6.94, the ratio declined again to 3.34 in 2021 and showed a marginal increase to 3.69 by the end of 2022. This instability suggests fluctuations in the volume of purchases or inconsistent payment strategies.
Average Payables Payment Period Trends
The average payables payment period exhibits a non-linear trajectory, shifting from 44 days in 2018 to 111 days in 2019. A brief reduction to 53 days occurred in 2020, followed by a return to extended payment terms of 109 days in 2021 and 99 days in 2022. The general shift from the 2018 baseline toward a cycle exceeding 90 days indicates a strategic or operational pivot toward delaying cash outflows to suppliers.
Working Capital Implications
The inverse relationship between the turnover ratio and the payment period is consistent throughout the period. The expansion of the payment period from 2019 onward, with the exception of 2020, suggests an increased reliance on trade credit to finance operations, thereby preserving liquidity at the expense of faster supplier settlement.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?